Index
1 Market Overview of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx)
1.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Overview
1.1.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Scope
1.1.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Status and Outlook
1.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (2018-2029)
1.4 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Region (2018-2023)
1.5 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2018-2029)
1.6.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2018-2029)
1.6.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2018-2029)
1.6.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2018-2029)
1.6.4 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2018-2029)
1.6.5 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2018-2029)
2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market by Type
2.1 Introduction
2.1.1 PCR
2.1.2 In-situ Hybridization
2.1.3 Immunohistochemistry
2.1.4 Sequencing
2.1.5 Others
2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Type (2018-2023)
2.2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Type (2018-2029)
3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Overview by Application
3.1 Introduction
3.1.1 Oncology
3.1.2 Neurological Disorders
3.1.3 Cardiovascular Disease
3.1.4 Immunological Disorders
3.1.5 Others
3.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Application (2018-2023)
3.2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Application (2018-2029)
4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Competition Analysis by Players
4.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) as of 2022)
4.3 Date of Key Players Enter into Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market
4.4 Global Top Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Headquarters and Area Served
4.5 Key Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Solution and Service
4.6 Competitive Status
4.6.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Qiagen NV
5.1.1 Qiagen NV Profile
5.1.2 Qiagen NV Main Business
5.1.3 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.1.4 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.1.5 Qiagen NV Recent Developments
5.2 GE Healthcare
5.2.1 GE Healthcare Profile
5.2.2 GE Healthcare Main Business
5.2.3 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.2.4 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.2.5 GE Healthcare Recent Developments
5.3 Agilent Technologies
5.3.1 Agilent Technologies Profile
5.3.2 Agilent Technologies Main Business
5.3.3 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.3.4 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.3.5 F Hoffman La Roche Recent Developments
5.4 F Hoffman La Roche
5.4.1 F Hoffman La Roche Profile
5.4.2 F Hoffman La Roche Main Business
5.4.3 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.4.4 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.4.5 F Hoffman La Roche Recent Developments
5.5 Foundation Medicine
5.5.1 Foundation Medicine Profile
5.5.2 Foundation Medicine Main Business
5.5.3 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.5.4 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.5.5 Foundation Medicine Recent Developments
5.6 Thermo Fisher Scientific Inc.
5.6.1 Thermo Fisher Scientific Inc. Profile
5.6.2 Thermo Fisher Scientific Inc. Main Business
5.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.6.4 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.6.5 Thermo Fisher Scientific Inc. Recent Developments
5.7 Leica Biosystems Nussloch GmBH
5.7.1 Leica Biosystems Nussloch GmBH Profile
5.7.2 Leica Biosystems Nussloch GmBH Main Business
5.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.7.4 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.7.5 Leica Biosystems Nussloch GmBH Recent Developments
5.8 Pfizer
5.8.1 Pfizer Profile
5.8.2 Pfizer Main Business
5.8.3 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.8.4 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.8.5 Pfizer Recent Developments
6 North America
6.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Dynamics
11.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industry Trends
11.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers
11.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Challenges
11.4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List